Blog
RSS FeedPosted by Michael Wonder on 14 May 2021
‘More reimbursement needed for hepatocellular carcinoma’
14 May 2021 - “Unlike other cancers, hepatocellular carcinoma is mostly diagnosed non-invasively. But this has not been reflected in ...
Posted by Michael Wonder on 13 May 2021
Eisai Korea to stop supply of blood cancer drug Symbenda this year
13 May 2021 - Symbenda (bendamustine), a treatment for blood cancer, is expected to become unavailable in Korea within this ...
Posted by Michael Wonder on 05 May 2021
Gilead readies to sell anticancer drug Trodelvy in Korea
4 May 2021 - Gilead’s antibody-drug conjugate Trodelvy (sacituzumab govitecan) has won the Ministry of Food and Drug Safety’s designation ...
Posted by Michael Wonder on 15 Apr 2021
Drug pricing policy in South Korea revised to ‘tiered pricing system’
14 April 2021 - The government announced a plan to restructure the generic drug pricing system with the main goal ...
Posted by Michael Wonder on 14 Apr 2021
Petition filed for better access to haemophilia A drug
14 April 2021 - Parents of paediatric patients with haemophilia A are demanding the regulator to change the criteria for ...
Posted by Michael Wonder on 07 Apr 2021
Janssen's prostate cancer drug gets reimbursement for mHSPC
6 April 2021 - Janssen said Tuesday that the government began providing health insurance benefits for its prostate cancer therapy ...
Posted by Michael Wonder on 17 Mar 2021
Zytiga to get insurance benefit for primary therapy in metastatic hormone-sensitive prostate cancer
17 March 2021 - Janssen Korea’s prostate cancer drug Zytiga (ingredient: abiraterone acetate) will get expanded insurance benefits for the ...
Posted by Michael Wonder on 07 Mar 2021
Primary dyslipidaemia drug Praluent gets insurance benefit
5 March 2021 - Sanofi-Aventis Korea’s primary dyslipidaemia treatment Praluent (alirocumab) has won health insurance benefits, the government said. ...
Posted by Michael Wonder on 24 Feb 2021
Takeda’s drug for acute hereditary angioedema seizure to get larger benefits
24 February 2021 - Takeda Pharmaceutical Korea said that the Ministry of Health and Welfare would grant expanded reimbursement for ...
Posted by Michael Wonder on 24 Feb 2021
Anti-cancer drugs Ninlaro, Lutathera to get insurance benefits from March
24 February 2021 - Takeda’s multiple myeloma treatment Ninlaro (ixazomib) and Novartis’ neuroendocrine tumour drug Lutathera (lutetium oxodotreotide) will get ...
Posted by Michael Wonder on 03 Feb 2021
Parkinson’s disease drug Equifina gets insurance benefits
1 February 2021 - The government has decided to grant health insurance benefits to Eisai’s Parkinson’s disease treatment, Equifina (safinamide), ...
Posted by Michael Wonder on 19 Jan 2021
Regulators OK Yuhan's Leclaza as 31st novel drug
18 January 2020 - Yuhan said Monday that it has received sales approval for Leclaza (lazertinib), a drug targeting epidermal ...
Posted by Michael Wonder on 12 Jan 2021
Janssen's ulcerative colitis treatment to receive reimbursement
12 January 2021 - Janssen Pharmaceutical said Tuesday that the Ministry of Health and Welfare would begin to reimburse Stelara, ...
Posted by Michael Wonder on 30 Dec 2020
Tiered drug pricing policy widens price difference among generic drugs
30 December 2020 - In July, the nation implemented a “tiered system” to restructure the drug-pricing method, which called for ...
Posted by Michael Wonder on 22 Oct 2020
Will HIRA resume talk to grant benefits for anti-diabetic combo drugs?
22 October 2020 - Three makers of SGLT-2 inhibiting anti-diabetic drugs said they would seek changes in approval conditions to ...